BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33161227)

  • 1. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy.
    Li Z; Chen S; Feng W; Luo Y; Lai H; Li Q; Xiu B; Li Y; Li Y; Huang S; Zhu X
    EBioMedicine; 2020 Dec; 62():103074. PubMed ID: 33161227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
    Liu H; Zhang B; Sun Z
    Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors.
    Daemen A; Manning G
    Breast Cancer Res; 2018 Jan; 20(1):8. PubMed ID: 29382369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
    Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
    Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
    Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
    Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 12. HER2 in solid tumors: more than 10 years under the microscope; where are we now?
    Martin V; Cappuzzo F; Mazzucchelli L; Frattini M
    Future Oncol; 2014 Jun; 10(8):1469-86. PubMed ID: 25052756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
    Kiss B; Wyatt AW; Douglas J; Skuginna V; Mo F; Anderson S; Rotzer D; Fleischmann A; Genitsch V; Hayashi T; Neuenschwander M; Buerki C; Davicioni E; Collins C; Thalmann GN; Black PC; Seiler R
    Sci Rep; 2017 Feb; 7():42713. PubMed ID: 28205537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-cancer evaluation of gene expression and somatic alteration data for cancer prognosis prediction.
    Zheng X; Amos CI; Frost HR
    BMC Cancer; 2021 Sep; 21(1):1053. PubMed ID: 34563154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
    Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
    Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
    Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
    Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
    Kim JY; Park K; Im SA; Jung KH; Sohn J; Lee KS; Kim JH; Yang Y; Park YH
    Breast Cancer Res Treat; 2020 Dec; 184(3):743-753. PubMed ID: 32860168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
    Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
    Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma HER2 (
    Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
    Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.